Community-acquired urinary tract infections in Southern Turkey: Etiology and antimicrobial resistance

Clinical Nephrology

Volumn 71, Issue 1, 2009, Pages 30-35

  Cetin, M ^a   Ucar, Edip ^b   Guven, O ^b   Ocak, S ^b  

^a University Faculty of Medicine   (Turkey)

^b Department of Internal Medicine ^*  (Turkey)

Author keywords

Bacterial resistance; Population survey; Urinary infection; Uropathogens

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFAZOLIN; CEFTRIAXONE; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; OFLOXACIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ESCHERICHIA COLI; FEMALE; HUMAN; KLEBSIELLA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PROTEUS; PSEUDOMONAS; TURKEY (REPUBLIC); URINARY TRACT INFECTION; COHORT ANALYSIS; COMMUNICABLE DISEASE; GRAM NEGATIVE INFECTION; GRAM POSITIVE INFECTION; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; PREVALENCE; RETROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; COHORT STUDIES; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; PREVALENCE; RETROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME; TURKEY; URINARY TRACT INFECTIONS;

EID: 63249115241     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71030     Document Type: Article

References (29)

1. Arslan H, Azap OK, Ergonul O, Timurkaynak F. Urinary Tract Infection Study Group. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey. J Antimicrob Chemother. 2005; 56: 914-918.
2. Barisic Z, Babic-Erceg A, Borzic E et al. Urinary tract infections in South Croatia: etiology and antimicrobial resistance. Int J Antimicrob Agents. 2003; 22: 61-64.
3. Barrett SP, Savage MA, Rebec MP et al. Antibiotic sensitivity of bacteria assosiated with community-acquired urinary tract infection in Britain. J Antimicrob Chemother. 1999; 44: 359-365.
4. Bassetti D, Bassetti M, Mantero E. Strategies for antibiotic selection in empirical therapy. Clin Microbiol Infect. 2000; 6: 98-100.
5. Chazan B, Sakran W, Raz R, Colodner R. Improved antimicrobial susceptibility of community-acquired uropathogens in northern Israel (1995, 1999, 2002). Int J Antimicrob Agents. 2004; 24: 89-92.
6. Chomarat M. Resistance of bacteria in urinary tract infections. Int J Antimicrob Agents. 2000; 16: 483-487.
7. Colodner R, Kenessa Y, Chazanb B et al. Antimicrobial susceptibility of community-acquired uropathogens in northern Israel. Int J Antimicrob Agents. 2001; 18: 189-192.
8. Daza R, Gutierrez J, Piedrola G. Antibiotic susceptibility of bacterial strains isolated from patients with community-acquired urinary tract infections. Int J Antimicrob Agents. 2000; 18: 211-215.
9. De Mouy D, Berges JL, Bouilloux JP et al. Sensibilité à la fosfomycine des principales bacteries issues d'infections urinaires observées en pratique de ville chez les femmes de 15-65 ans. Med Mal Infect. 1997; 27: 903-906.
10. Dimitrov TS, Udo EE, Emara M et al. Etiology and antibiotic susceptibility patterns of community-acquired urinary tract infections in a Kuwait hospital. Med Princ Pract. 2004; 13: 334-339.
11. Dromigny JA, Nabeth P, Perrier G, Claude JD. Distribution and susceptibility of bacterial urinary tract infections in Dakar, Senegal. Int J Antimicrob Agents. 2002; 20: 339-347.
12. Dyer IE, Sankary TM, Dawson JA. Antibiotic resistance in bacterial urinary tract infections 1991-1997. West J Med. 1998; 169: 265-268.
13. Farra A, Skoog G, Wallen L et al. Antibiotic use and Escherichia coli resistance trends for quinolones and cotrimoxazole in Sweden. Scand J Infect Dis. 2002; 34: 449-455.
14. Farrell DJ, Morrissey I, De Rubeis D, Robbins M, Felmingham D. AUK multicentre study of the antimicrobial susceptibility of bacterial pathogens causing urinary tract infection. J Infect. 2002; 46: 94-100.
15. Kahlmeter G. An international survey of the antimicrobial susceptibility of pathogens from uncomplicated urinary tract infections: the ECO.SENS Project. J Antimicrob Chemother. 2003; 51: 69-76.
16. Gales AC, Jones RN, Gordon KA et al. Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: report from the second year of the SENTRY Antimicrobial Surveillance Program. J Antimicrob Chemother. 2000; 45: 295-303.
17. Grude N, Tveten Y, Kristiansen BE. Urinary tract infections in Norway: bacterial etiology and susceptibility. A retrospective study of clinical isolates. Clin Microbiol Infect. 2001; 7: 543-547.
18. Kahlmeter G. The ECO-SENS project: a prospective, multinational multicentre epidemiological survey of the prevalence and antimicrobial susceptibility of urinary tract pathogens-interim report. J Antimicrob Chemother. 2000; 46: 15-22.
19. Karaca Y, Coplu N, Gozalan A et al. Cotrimoxazole and quinolone resistance in Escherichia coli isolated from urinary tract infections over the last 10 years. Int J Antimicrob Agents. 2005; 26: 75-77.
20. Kurutepe S, Surucuoglu S, Sezgin C et al. Increasing antimicrobial resistance in Escherichia coli isolates from community-acquired urinary tract infections during 1998-2003 in Manisa, Turkey. Jpn J Infect Dis. 2005; 58: 159-161.
21. Matute AJ, Hak E, Schurink CA et al. Resistance of uropathogens in symptomatic urinary tract infections in Leon, Nicaragua. Int J Antimicrob Agents. 2004; 23: 506-509.
22. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing. 11th informational supplement. 2001; M100-S11. Wayne NCCLS.
23. Papapetropoulou M, Pagonopoulou O, Kouskouni E. Prevalence and sensitivity to antibiotics of Enterobacteriaceae isolated from urinary cultures in some microbiology laboratories of a city in west Greece. Pathol Biol (Paris). 1997; 45: 716-720.
24. Raka L, Mulliqi-Osmani M, Berisha L et al. Etiology and susceptibility of urinary tract isolates in Kosova. Int J Antimicrob Agents. 2004; 23: 2-5.
25. Sahm D, Thornsbery C, Mayfield D et al. Multidrug-resistant urinary tract isolates of Escherichia coli: prevalence and patient demographics in the United States in 2000. Antimicrob Agents Chemother. 2001; 45: 1402-1406.
26. Talan DA, Naber KG, Palou J et al. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. Int J Antimicrob Agents. 2004; 23: 54-66.
27. Ti TY, Kumarasinghe G, Taylor MB et al. What is true community-acquired urinary tract infection? Comparison of pathogens identified in urine from routine out-patient specimens and from community clinics in a prospective study. Eur J Clin Microbiol Infect Dis. 2003; 22: 242-245.
28. Warren JW, Abrutyn E, Hebel JR et al. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Clin Infect Dis. 2004; 29: 745-758.
29. Zhanel G, Karlowsky J, Harding G et al. The Canadian Urinary Isolate Study Group and Low D. A Canadian national surveillance study of urinary tract isolates from outpatients: comparison of the activities of trimethoprim-sulfamethoxasole, ampicillin, mecillinam, nitrofurantoin and ciprofloxacin. Antimicrob Agents Chemother. 2000; 44: 1089-1092.